First Tracks Biotherapeutics arrives at its August 14 earnings event with the short side in clear retreat and the analyst community converging on the upside — a combination that sets a high bar for the print.
Short sellers have been covering steadily. Estimated short interest fell roughly 13% in a single session on August 11, and is down nearly 16% on the week, pulling back from a mid-July peak. The borrow market tells the same story in the other direction: availability is loose at 517%, meaning there are more than five shares available to borrow for every share currently shorted. Cost to borrow has collapsed — down nearly 80% over the past month — after briefly spiking above 1.9% in mid-July. That earlier spike has fully unwound. There is no squeeze pressure in the lending market, and shorts appear to be stepping back rather than pressing into the binary event.
Options traders are slightly more cautious than usual, but not dramatically so. The put/call ratio moved up to 0.61 on Wednesday, running above its 20-day average of 0.52 — a modest shift toward hedging. That reading is still comfortably below the 52-week peak of 0.88, which hit in mid-July when the stock was weaker. The current positioning looks more like routine pre-earnings protection than a directional bet against the company.
The analyst tone since the prior preview article has not changed: the direction-of-travel remains uniformly bullish. UBS raised its target from $45 to $65 on August 10, the most recent and most aggressive move. The consensus mean has edged up to $60.50, now a 31% premium to the $46.13 close. Every recent revision — UBS, Wedbush, Wells Fargo, Barclays — has been an upward target increase with no rating change. Sanofi's presence on the shareholder register alongside institutional names like EcoR1, FMR, and BlackRock adds a strategic dimension to the ownership picture. The bull case rests on rosnilimab's Phase 2b readouts and the size of the addressable market in eosinophilic esophagitis and celiac disease. Bears flag the obvious: no approved products, ongoing cash burn, and the phase-dependent nature of all near-term value.
The print is therefore a test of whether the clinical data embedded in a 27% one-month rally is real progress or anticipation — and whether the pipeline updates justify targets that now cluster well above the current price.
See the live data behind this article on ORTEX.
Open TRAX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
